
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Companion Diagnostics from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/companion-diagnostics/topic/13759/</link>
        <description>Articles tagged with Companion Diagnostics from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Tarceva diagnostic brings new indication</title>
          <description>Tarceva picks up a first-line indication and a companion diagnostic</description>
          <link>http://www.mmm-online.com/tarceva-diagnostic-brings-new-indication/article/293523/</link>
          <pubDate>Wed, 15 May 2013 16:45:18 GMT</pubDate>
          <itunes:summary>Tarceva picks up a first-line indication and a companion diagnostic</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Tysabri gets boost from label change, new diagnostic</title>
          <description>Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug&apos;s label that could boost sales by helping doctors avoid a serious adverse event.</description>
          <link>http://www.mmm-online.com/tysabri-gets-boost-from-label-change-new-diagnostic/article/224378/</link>
          <pubDate>Mon, 23 Jan 2012 22:23:18 GMT</pubDate>
          <itunes:summary>Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug&apos;s label that could boost sales by helping doctors avoid a serious adverse event.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Pfizer&apos;s Xalkori and Abbott test show promise in personalized medicine, companion diagnostics</title>
          <description>The FDA&apos;s approval of Pfizer&apos;s Xalkori (crizotinib) represents a leap forward for both personalized medicine and Pfizer&apos;s R&amp;D turnaround, but its commercial success hinges on a pricey diagnostic array by Abbott&apos;s Vysis.</description>
          <link>http://www.mmm-online.com/pfizers-xalkori-and-abbott-test-show-promise-in-personalized-medicine-companion-diagnostics/article/210898/</link>
          <pubDate>Tue, 30 Aug 2011 19:53:28 GMT</pubDate>
          <itunes:summary>The FDA&apos;s approval of Pfizer&apos;s Xalkori (crizotinib) represents a leap forward for both personalized medicine and Pfizer&apos;s R&amp;D turnaround, but its commercial success hinges on a pricey diagnostic array by Abbott&apos;s Vysis.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  